Amsterdam Psychedelic Research Association (APRA) on LinkedIn: A review article by Inserra et al. (2023) published in CNS Drugs discusses… (2024)

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF)is advancing two major Phase 2 clinical trial programs using its novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.Enrolment continues to track well in Actinogen’s six-week XanaCIDD Phase 2a depression clinical trial at Australian and UK sites, which now exceeds 75% of the planned 160 trial participants.This XanaCIDD study aims to investigate the safety and efficacy of Xanamem drug substance in patients with cognitive impairment associated with persistent major depressive disorder (MDD).Results for this trial are expected in Q2 CY2024.Meanwhile, trial site activation and participant screening have started in the XanaMIA Phase 2b Alzheimer’s disease trial.More at #Proactive #ProactiveInvestors #ASX #OTC #ACW #ATGGF #depression #Alzheimer’s #treatment http://ow.ly/Foof105jZvG

2

#CentralNervousSystem #Therapeutics Industry is projected to witness a CAGR of 8% during the period 2023-2032. This growth can be attributed to the increasing prevalence of CNS disorders.

1

#CentralNervousSystem #Therapeutics Industry is projected to witness a CAGR of 8% during the period 2023-2032. This growth can be attributed to the increasing prevalence of CNS disorders.

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

Join Dr. John Oldenhof and other top-notch medical professionals from abroad as they discuss the latest in epilepsy treatments and diagnostic tools at #AES2023.Connect with Dr. Oldenhof and learn about his personal connection.December 1-5 | Orange County Convention Center (West Concourse) | Orlando, Florida. Interested in reading more about Dr. Oldenhofs story? Click the link below.https://hubs.li/Q02bCDtV0Meeting 🔗 https://hubs.li/Q02bCGKc0BioPharma Services Inc. specializes in #Phase1 clinical trials, BA/BE, First-in-Human and Human Abuse Potential Studies (#HAP). Let our world-renowned #Pharmaco*kinetics team execute your next clinical trial with confidence....#clinicalresearch #clinicalstudies #clinicaltrials #bioanalsysis #cro #clinicaltrials #Biopharma #drugdevelopment #epilepsy #epilepsytreatment #epilepsyresearch

15

Compared to other areas of drug discovery, the clinical failure rate for new drugs targeting Central Nervous System (CNS) diseases is higher. But we have an incredible track record of drug discovery for CNS disorders with extensive knowledge of disease mechanisms. 👉 Get in touch with IBS for successful progression from candidate identification to clinical trial design and advance your drug discovery research in a promising way--------#drug #discovery #central #nervous #system #disease #medicines #CNS #ibs #bioscience #research

8

Nyrada Inc. (ASX:NYR) today provided an update on its Brain Injury Program confirming commencement of Good Laboratory Practice (GLP) safety testing studies for NYR-BI03.Subject to positive outcomes these GLP studies, a first-in-human Phase I clinical trial for NYR-BI03 will commence in 2HCY2024. To access a full copy of the announcement, please click on the following link: https://bit.ly/3PJuOon Nyrada CEO James Bonnar commented: “NYR-BI03 is a first-in-class therapy with a novel mechanism of action targeting significant market opportunity. Stroke and traumatic brain injury are leading causes of death and disability worldwide with no current FDA approved treatments. “Given the strong efficacy and positive safety signals from our preclinical stroke study, we have now commenced the necessary GLP studies that will lead to human trials for NYR-BI03. This is a very exiting phase for Nyrada and our Brain Injury Program.”Nyrada also confirmed that the full $1.755 million of new equity capital (before costs) from its March 2024 capital raise has been received. A further $0.210 million is expected in May 2024 following the Company’s Extraordinary General Meeting (EGM) provisionally scheduled for 16 May 2024.

11

1 Comment

What would a trial that includes patients with borderline personality disorder look like? Our Christine Moore, PhD shares considerations for how to enroll this historically challenging to include patient population in our new blog:https://ow.ly/1BWJ50REQw7You can hear more from Christine on the methodology for including these patients at Psychedelic Therapeutics & Drug Development Conference later this month. Learn more or register to meet with her: https://ow.ly/qM5v50REQyr

43

1 Comment

🚀 Exciting News in Schizophrenia Treatment! 🧠Newron Pharmaceuticals SpA Pharmaceuticals just announced ground-breaking results from their Phase 2/3 trial of evenamide in chronic schizophrenia patients. The study, assessing evenamide as an add-on to existing antipsychotic therapy, achieved its primary endpoint of improving symptoms measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.🔍 What makes evenamide unique? It selectively blocks voltage-gated sodium channels (VGSCs) with no detectable effects on over 130 other CNS targets. Plus, it demonstrated a favorable safety profile in the trial, with a high completion rate among patients.👨⚕️ Dr. Ravi Anand, Chief Medical Officer at Newron Pharmaceuticals, hailed these results as groundbreaking, highlighting evenamide's potential to offer new hope to patients who haven't responded well to current treatments.🔬 With plans for a Phase 3 trial underway, Newron Pharmaceuticals is at the forefront of developing innovative therapies for CNS disorders. Stay tuned for more updates on this promising development! 🌟 For more news like this, please follow the World Pharmaceutical Frontiers page!!#SchizophreniaResearch #Evenamide #InnovationInHealthcare #worldpharmaceuticalfrontiers

1

The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years. Among them are notable advancements in psychiatric medications. The antidepressant Gepirone, a 5HT1A receptor agonist, offers new hope for individuals with major depressive disorder. Additionally, Zuranolone, a GABA_A receptor positive allosteric modulator (PAM), targets the challenging area of postpartum depression, providing a specialized treatment option. It's also worth mentioning Fezolinetant, a neurokinin 3 (NK3) receptor antagonist. While its primary indication is for treating hot flashes during menopause, the psychological impact of vasomotor symptoms on mood makes it a compound of potential interest to psychiatrists. https://lnkd.in/ecnB5Jwx

15

2 Comments